I suspect we'll understand better after MSKCC presents their system for determining bone-based responses at ASCO.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr